The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large b cell lymphoma: Update of the 2001 evidence-based review

Denise M. Oliansky, Myron Czuczman, Richard I. Fisher, Frank D. Irwin, Hillard M. Lazarus, James Omel, Julie Marie Vose, Steven N. Wolff, Roy B. Jones, Philip L. McCarthy, Theresa Hahn

Research output: Contribution to journalReview article

59 Citations (Scopus)

Abstract

Clinical research published since the 2001 evidence-based review on the role of hematopoietic stem cell transplantation (SCT) in the treatment of diffuse large B cell lymphoma (DLBCL) in adults is presented and critically evaluated in this update. Treatment recommendations that remain unchanged from the original review include: (1) autologous SCT as salvage therapy is recommended for patients with chemosensitive relapsed DLBCL; and (2) autologous SCT is not recommended for patients who achieve a partial response to an abbreviated induction regimen. New treatment recommendations based on new published data include: (1) autologous SCT as first-line therapy is not recommended for any IPI group; (2) planned tandem or multiple sequential autologous SCT is not recommended; (3) peripheral blood is the standard stem cell source for autologous SCT; (4) age is not a contraindication for autologous SCT, although outcomes in older adults are not as good as in younger adults. There are insufficient data to make recommendations on the routine use of rituximab maintenance after autologous SCT, autologous versus allogeneic SCT, fewer versus more cycles of induction therapy prior to autologous SCT, or the use of reduced intensity versus myeloablative conditioning regimens. Areas of needed research in the treatment of DLBCL with SCT were identified and are presented in the review.

Original languageEnglish (US)
Pages (from-to)20-47.e30
JournalBiology of Blood and Marrow Transplantation
Volume17
Issue number1
DOIs
StatePublished - Jan 2011

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Hematopoietic Stem Cell Transplantation
Stem Cell Transplantation
Therapeutics
Salvage Therapy
Research
Young Adult
Stem Cells
Maintenance

Keywords

  • Adult
  • Diffuse large B cell lymphoma
  • Hematopoietic stem cell transplantation
  • Systematic evidencebased review
  • Therapy

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large b cell lymphoma : Update of the 2001 evidence-based review. / Oliansky, Denise M.; Czuczman, Myron; Fisher, Richard I.; Irwin, Frank D.; Lazarus, Hillard M.; Omel, James; Vose, Julie Marie; Wolff, Steven N.; Jones, Roy B.; McCarthy, Philip L.; Hahn, Theresa.

In: Biology of Blood and Marrow Transplantation, Vol. 17, No. 1, 01.2011, p. 20-47.e30.

Research output: Contribution to journalReview article

Oliansky, Denise M. ; Czuczman, Myron ; Fisher, Richard I. ; Irwin, Frank D. ; Lazarus, Hillard M. ; Omel, James ; Vose, Julie Marie ; Wolff, Steven N. ; Jones, Roy B. ; McCarthy, Philip L. ; Hahn, Theresa. / The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large b cell lymphoma : Update of the 2001 evidence-based review. In: Biology of Blood and Marrow Transplantation. 2011 ; Vol. 17, No. 1. pp. 20-47.e30.
@article{088e97a7d09849b5893c7fc0f1c9f1d1,
title = "The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large b cell lymphoma: Update of the 2001 evidence-based review",
abstract = "Clinical research published since the 2001 evidence-based review on the role of hematopoietic stem cell transplantation (SCT) in the treatment of diffuse large B cell lymphoma (DLBCL) in adults is presented and critically evaluated in this update. Treatment recommendations that remain unchanged from the original review include: (1) autologous SCT as salvage therapy is recommended for patients with chemosensitive relapsed DLBCL; and (2) autologous SCT is not recommended for patients who achieve a partial response to an abbreviated induction regimen. New treatment recommendations based on new published data include: (1) autologous SCT as first-line therapy is not recommended for any IPI group; (2) planned tandem or multiple sequential autologous SCT is not recommended; (3) peripheral blood is the standard stem cell source for autologous SCT; (4) age is not a contraindication for autologous SCT, although outcomes in older adults are not as good as in younger adults. There are insufficient data to make recommendations on the routine use of rituximab maintenance after autologous SCT, autologous versus allogeneic SCT, fewer versus more cycles of induction therapy prior to autologous SCT, or the use of reduced intensity versus myeloablative conditioning regimens. Areas of needed research in the treatment of DLBCL with SCT were identified and are presented in the review.",
keywords = "Adult, Diffuse large B cell lymphoma, Hematopoietic stem cell transplantation, Systematic evidencebased review, Therapy",
author = "Oliansky, {Denise M.} and Myron Czuczman and Fisher, {Richard I.} and Irwin, {Frank D.} and Lazarus, {Hillard M.} and James Omel and Vose, {Julie Marie} and Wolff, {Steven N.} and Jones, {Roy B.} and McCarthy, {Philip L.} and Theresa Hahn",
year = "2011",
month = "1",
doi = "10.1016/j.bbmt.2010.07.008",
language = "English (US)",
volume = "17",
pages = "20--47.e30",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large b cell lymphoma

T2 - Update of the 2001 evidence-based review

AU - Oliansky, Denise M.

AU - Czuczman, Myron

AU - Fisher, Richard I.

AU - Irwin, Frank D.

AU - Lazarus, Hillard M.

AU - Omel, James

AU - Vose, Julie Marie

AU - Wolff, Steven N.

AU - Jones, Roy B.

AU - McCarthy, Philip L.

AU - Hahn, Theresa

PY - 2011/1

Y1 - 2011/1

N2 - Clinical research published since the 2001 evidence-based review on the role of hematopoietic stem cell transplantation (SCT) in the treatment of diffuse large B cell lymphoma (DLBCL) in adults is presented and critically evaluated in this update. Treatment recommendations that remain unchanged from the original review include: (1) autologous SCT as salvage therapy is recommended for patients with chemosensitive relapsed DLBCL; and (2) autologous SCT is not recommended for patients who achieve a partial response to an abbreviated induction regimen. New treatment recommendations based on new published data include: (1) autologous SCT as first-line therapy is not recommended for any IPI group; (2) planned tandem or multiple sequential autologous SCT is not recommended; (3) peripheral blood is the standard stem cell source for autologous SCT; (4) age is not a contraindication for autologous SCT, although outcomes in older adults are not as good as in younger adults. There are insufficient data to make recommendations on the routine use of rituximab maintenance after autologous SCT, autologous versus allogeneic SCT, fewer versus more cycles of induction therapy prior to autologous SCT, or the use of reduced intensity versus myeloablative conditioning regimens. Areas of needed research in the treatment of DLBCL with SCT were identified and are presented in the review.

AB - Clinical research published since the 2001 evidence-based review on the role of hematopoietic stem cell transplantation (SCT) in the treatment of diffuse large B cell lymphoma (DLBCL) in adults is presented and critically evaluated in this update. Treatment recommendations that remain unchanged from the original review include: (1) autologous SCT as salvage therapy is recommended for patients with chemosensitive relapsed DLBCL; and (2) autologous SCT is not recommended for patients who achieve a partial response to an abbreviated induction regimen. New treatment recommendations based on new published data include: (1) autologous SCT as first-line therapy is not recommended for any IPI group; (2) planned tandem or multiple sequential autologous SCT is not recommended; (3) peripheral blood is the standard stem cell source for autologous SCT; (4) age is not a contraindication for autologous SCT, although outcomes in older adults are not as good as in younger adults. There are insufficient data to make recommendations on the routine use of rituximab maintenance after autologous SCT, autologous versus allogeneic SCT, fewer versus more cycles of induction therapy prior to autologous SCT, or the use of reduced intensity versus myeloablative conditioning regimens. Areas of needed research in the treatment of DLBCL with SCT were identified and are presented in the review.

KW - Adult

KW - Diffuse large B cell lymphoma

KW - Hematopoietic stem cell transplantation

KW - Systematic evidencebased review

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=79956196646&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956196646&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2010.07.008

DO - 10.1016/j.bbmt.2010.07.008

M3 - Review article

C2 - 20656046

AN - SCOPUS:79956196646

VL - 17

SP - 20-47.e30

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 1

ER -